Catalyst Financial Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

Catalyst Financial Partners’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$212K	Hold	89,699	–	–	0.03%	358
2025 Q4	$189K	Hold	89,699	–	–	0.02%	323
2025 Q3	$153K	Hold	89,699	–	–	0.02%	314
2025 Q2	$104K	Hold	89,699	–	–	0.01%	302
2025 Q1	$98.7K	Hold	89,699	–	–	0.02%	286
2024 Q4	$154K	Hold	89,699	–	–	0.03%	272
2024 Q3	$222K	Hold	89,699	–	–	0.04%	245
2024 Q2	$217K	Hold	89,699	–	–	0.05%	227
2024 Q1	$311K	Hold	89,699	–	–	0.08%	166
2023 Q4	$344K	Hold	89,699	–	–	0.1%	145
2023 Q3	$372K	Hold	89,699	–	–	0.12%	126
2023 Q2	$431K	Buy	+89,699	New	+$429K	0.15%	98

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Catalyst Financial Partners's ABOS Position: Q1 2026 in Review

Catalyst Financial Partners held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 89,699 shares worth $212K. The position accounts for 0.03% of the portfolio, ranked #358.

Catalyst Financial Partners first reported a position in ABOS in Q2 2023 and has held it in 12 quarters since. The position peaked at $431K in Q2 2023. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Catalyst Financial Partners held 89,699 shares of Acumen Pharmaceuticals worth $212K as of Q1 2026.
Catalyst Financial Partners left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
Acumen Pharmaceuticals made up 0.03% of Catalyst Financial Partners's portfolio in Q1 2026, its #358 holding.
Catalyst Financial Partners first reported a position in Acumen Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Catalyst Financial Partners's Acumen Pharmaceuticals position peaked at $431K in Q2 2023.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Catalyst Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.